Edition:
India

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

84.77USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$84.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
285,842
52-wk High
$97.34
52-wk Low
$60.28

Latest Key Developments (Source: Significant Developments)

Sanofi and U.S. peer Alnylam conclude research and option phase of 2014 rare disease alliance
Monday, 8 Apr 2019 

April 8 (Reuters) - Sanofi SA ::* Sanofi and Alnylam have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases. .* As part of this agreement, Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease through the end of IND-enabling studies..* Sanofi will be responsible for any potential further development or commercialization of such asset. If this product is approved, Alnylam will be eligible to receive tiered double-digit royalties on its global net sales..* In addition, Alnylam and Sanofi have agreed to amend certain terms of the companies' equity agreement, with Sanofi obtaining a release of its lock-up of Alnylam stock holdings, subject to certain trading restrictions, amongst other provisions.  Full Article

Alnylam Says Givosiran Meets Main Goal In Late-Stage Study
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM REPORTS POSITIVE TOPLINE RESULTS FROM ENVISION PHASE 3 STUDY OF GIVOSIRAN IN ACUTE HEPATIC PORPHYRIA.ALNYLAM PHARMACEUTICALS INC - GIVOSIRAN MEETS PRIMARY AND MAJORITY OF SECONDARY ENDPOINTS.ALNYLAM PHARMACEUTICALS INC - INTENDS TO COMPLETE FILING OF NEW DRUG APPLICATION (NDA) AND MARKETING AUTHORISATION APPLICATION (MAA) IN MID-2019.ALNYLAM PHARMACEUTICALS INC - FULL RESULTS TO BE PRESENTED AT EUROPEAN ASSOCIATION FOR STUDY OF LIVER (EASL) INTERNATIONAL LIVER CONGRESS IN APRIL.  Full Article

Alnylam Pharmaceuticals Reports Q4 Loss Per Share Of $2.09
Friday, 8 Feb 2019 

Feb 7 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY.Q4 NON-GAAP LOSS PER SHARE $1.82.Q4 EARNINGS PER SHARE ESTIMATE $-2.27 -- REFINITIV IBES DATA.ALNYLAM EXPECTS ITS 2019 ANNUAL NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $520 TO $560 MILLION.ALNYLAM EXPECTS ITS 2019 NON-GAAP SG&A EXPENSES TO BE IN RANGE OF $390 TO $420 MILLION..ALNYLAM - EXPECTS ITS CURRENT CASH, CASH EQUIVALENTS, AND MARKETABLE DEBT SECURITIES WILL SUPPORT COMPANY OPERATIONS FOR APPROXIMATELY TWO YEARS.Q4 GAAP LOSS PER SHARE $2.09.  Full Article

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock
Tuesday, 15 Jan 2019 

Jan 14 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.ALNYLAM PHARMACEUTICALS INC- PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 5 MILLION SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $77.50 PER SHARE.ALNYLAM PHARMACEUTICALS INC - GROSS PROCEEDS FROM OFFERING ARE EXPECTED TO BE APPROXIMATELY $387.5 MILLION.  Full Article

Alnylam Pharmaceuticals Announces Proposed Public Offering Of 5 Mln Common Shares
Tuesday, 15 Jan 2019 

Jan 14 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 5.00 MILLION COMMON SHARES.  Full Article

Alnylam Reports Q4 Onpattro Net Product Revenues Of $11-12 MLn
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM ANNOUNCES UNAUDITED FOURTH QUARTER 2018 GLOBAL REVENUES FOR ONPATTRO (PATISIRAN) AND PROVIDES ADDITIONAL COMMERCIAL UPDATES.ALNYLAM PHARMACEUTICALS INC - Q4 2018 ONPATTRO UNAUDITED GLOBAL NET PRODUCT REVENUES OF $11-12 MILLION.  Full Article

Alnylam Pharmaceuticals reports third quarter results
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY.Q3 LOSS PER SHARE $2.43.Q3 NON-GAAP LOSS PER SHARE $1.56.Q3 EARNINGS PER SHARE VIEW $-2.02 -- THOMSON REUTERS I/B/E/S.RECEIVED 125 U.S. PATIENT START FORMS IN FIRST SEVEN WEEKS OF ONPATTRO LAUNCH.ALNYLAM PHARMACEUTICALS - REPORTED POSITIVE TOPLINE INTERIM ANALYSIS RESULTS FROM ENVISION PHASE 3 STUDY OF GIVOSIRAN IN PATIENTS WITH ACUTE HEPATIC PORPHYRIAS.OBTAINED FDA AND EMA APPROVALS OF ONPATTRO™ (PATISIRAN) AND LAUNCHED IN U.S. AND EU.QTRLY TOTAL REVENUES $2.1 MILLION VERSUS $17.1 MILLION.COMPANY REITERATES ITS EXPECTATIONS FOR 2018 ANNUAL NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN THE RANGE OF $420 MILLION TO $460 MILLION.  Full Article

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM REPORTS UPDATED POSITIVE RESULTS FROM PHASE 1/2 STUDY OF LUMASIRAN IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1.ALNYLAM PHARMACEUTICALS INC - LUMASIRAN SHOWS ENCOURAGING SAFETY PROFILE WITH A MEDIAN OF SEVEN MONTHS AND UP TO 14 MONTHS STUDY DURATION.ALNYLAM PHARMACEUTICALS INC - ALSO ANNOUNCED INITIATION OF ILLUMINATE-A, A GLOBAL PHASE 3 PIVOTAL TRIAL OF LUMASIRAN IN CHILDREN AND ADULTS WITH PH1.ALNYLAM PHARMACEUTICALS INC - LUMASIRAN TREATMENT RESULTED IN 75 PERCENT MEAN MAXIMAL REDUCTION IN URINARY OXALATE RELATIVE TO BASELINE.ALNYLAM PHARMACEUTICALS INC - EXPECTS TO REPORT TOPLINE RESULTS FROM ILLUMINATE-A IN LATE 2019.  Full Article

Alnylam Announces Positive Topline Results From Interim Analysis Of Envision Phase 3 Study Of Givosiran In Patients With Acute Hepatic Porphyria
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM ANNOUNCES POSITIVE TOPLINE RESULTS FROM INTERIM ANALYSIS OF ENVISION PHASE 3 STUDY OF GIVOSIRAN IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA.ALNYLAM PHARMACEUTICALS INC - TOPLINE RESULTS ON PRIMARY ENDPOINT OF ANNUALIZED ATTACK RATE EXPECTED IN EARLY 2019.ALNYLAM PHARMACEUTICALS INC - TOPLINE RESULTS ON PRIMARY ENDPOINT OF ANNUALIZED ATTACK RATE EXPECTED IN EARLY 2019 -.ALNYLAM PHARMACEUTICALS INC - COMPANY PLANS TO DISCUSS RESULTS WITH FDA REGARDING A POTENTIAL NDA FILING AT OR AROUND YEAR-END IN SUPPORT OF AN ACCELERATED APPROVAL.ALNYLAM PHARMACEUTICALS INC - PLANS TO DISCUSS RESULTS WITH FDA REGARDING POTENTIAL NDA FILING AT OR AROUND YEAR-END IN SUPPORT OF AN ACCELERATED APPROVAL.ALNYLAM PHARMACEUTICALS - GIVOSIRAN TREATMENT RESULTED IN SIGNIFICANT REDUCTION OF URINARY AMINOLEVULINIC ACID.ALNYLAM PHARMACEUTICALS - NO DEATHS, AND SERIOUS ADVERSE EVENTS REPORTED IN 22 PERCENT OF GIVOSIRAN PATIENTS AND 10 PERCENT OF PLACEBO PATIENTS.  Full Article

Alnylam Completes Enrollment In Envision Phase 3 Study Of Givosiran
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM COMPLETES ENROLLMENT IN ENVISION PHASE 3 STUDY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF ACUTE HEPATIC PORPHYRIAS (AHPS).ALNYLAM PHARMACEUTICALS INC - ON TRACK TO REPORT INTERIM ANALYSIS DATA BY END OF SEPTEMBER AND FULL STUDY DATA IN EARLY 2019.ALNYLAM PHARMACEUTICALS INC - EXPECT TO SUBMIT AN NDA AT OR AROUND YEAR-END 2018, SEEKING AN ACCELERATED APPROVAL.  Full Article

Regeneron second-quarter revenue beats on Eylea sales

Aug 6 Regeneron Pharmaceuticals Inc reported better-than-expected quarterly revenue on Tuesday, boosted by demand for its blockbuster eye drug, Eylea.